EP Patent

EP1117396A1 — A method to increase the excretion of non-sterol endogenous hydrophobic substances by increasing excretion of fat via the faeces

Assigned to Individual · Expires 2001-07-25 · 25y expired

What this patent protects

The subject invention concerns a method to increase the excretion of non-sterol endogenous hydrophobic substances or metabolic derivatives thereof by increasing excretion via the faeces of the hydrophobic substance or metabolic derivative thereof characterisedin that the excretio…

USPTO Abstract

The subject invention concerns a method to increase the excretion of non-sterol endogenous hydrophobic substances or metabolic derivatives thereof by increasing excretion via the faeces of the hydrophobic substance or metabolic derivative thereof characterisedin that the excretion of fat via the faeces is increased. The purpose of the invention is to prevent or treat conditions associated with the accumulation of non-sterol endogenous hydrophobic substances or metabolic derivatives thereof, such substances being unconjugated bilirubin and protoporphyrin. More particularly, lipstatin, orlistat, tetrahydrolipstatin, polyol fatty acids like olestra, and non-conventional doses of dietary jet are used to treat neonatal jaundice, haemolytic or erythropoietic protoporphyria.

Drugs covered by this patent

Patent Metadata

Patent number
EP1117396A1
Jurisdiction
EP
Classification
Expires
2001-07-25
Drug substance claim
No
Drug product claim
No
Assignee
Individual
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.